Therapeutic Response Statement (Sensitivity) Deprecated

This therapeutic response statement Supports the relationship that HER2-negative and PR positive status confers therapeutic sensitivity to Fulvestrant, Palbociclib in patients with Invasive Breast Carcinoma.

The Republic of Ireland's Health Service Executive (HSE) has approved palbociclib in combination with fulvestrant as a treatment option for the treatment of patients who are women with (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received prior endocrine therapy.

This statement is based on a regulatory approval from the Health Service Executive:

Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy

Citation

Palbociclib Therapy - 28 day, 2025, version number 5, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6457/414_v5_Palbociclib_o9nHDn7.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2018-06-01	Health Service Executive	Indication approved for reimbursement.